TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit fi ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit fi ...

Core Viewpoint - Cemtrex, Inc. has announced a public offering of common stock expected to raise approximately $1.25 million before expenses [1][3]. Group 1: Offering Details - The offering consists of 1,250,000 shares of common stock priced at $1.00 per share [2]. - Aegis Capital Corp. has been granted a 45-day option to purchase up to 15% additional shares to cover over-allotments [2]. - The transaction is expected to close on or about May 29, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, paying down indebtedness, and working capital [3]. Group 3: Company Overview - Cemtrex, Inc. operates in the Security and Industrial sectors, providing advanced security technology and industrial services [7]. - The Security segment, led by Vicon Industries, offers video management software and integrated surveillance solutions [7]. - The Industrial segment provides expert rigging, millwrighting, and equipment installation services to manufacturers [7].

SHANGHAI, China, May 27, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced the commencement of a proposed offering of 5,200,000 American Depositary Shares (“ADSs”), each representing eight Class A ordinary shares, par value US$0.00005 per share, subject to market and other conditions, in an underwritten registered public offering (the “Primary ADSs Offer ...

Core Viewpoint - Outlook Therapeutics, Inc. has announced a public offering of 9,285,714 shares of common stock at a price of $1.40 per share, along with warrants to purchase an additional 18,571,428 shares, aiming to raise approximately $13.0 million in gross proceeds [1][2]. Group 1: Offering Details - The public offering includes common stock sold in combination with warrants, where each share sold comes with a warrant to purchase two additional shares at an exercise price of $1.40 [1]. - The offering is expected to close on May 27, 2025, pending customary closing conditions [1]. - BTIG, LLC is acting as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [2]. Group 3: Company Overview - Outlook Therapeutics focuses on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), aimed at enhancing the standard of care for retinal diseases [5]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for treating wet age-related macular degeneration (wet AMD) [5]. - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and the UK in the second quarter of 2025, while the product remains investigational in the United States [5].

LAS VEGAS, May 22, 2025 /PRNewswire/ -- Southwest Gas Holdings, Inc. (NYSE: SWX) ("Southwest Gas Holdings" or the "Company") today announced the closing of its underwritten secondary public offering of Centuri Holdings, Inc. (NYSE: CTRI) ("Centuri") common stock (the "Offering"). Southwest Gas Holdings, as the selling stockholder, sold 10,350,000 existing shares of Centuri's common stock at a public offering price of $17.50 per share (the "Offering Price"), including the underwriters' full exercise of their ...

Core Viewpoint - Gyre Therapeutics has initiated an underwritten public offering of its common stock to fund its clinical trials and operational needs [1][2]. Group 1: Offering Details - Gyre is granting underwriters a 30-day option to purchase additional shares at the public offering price, subject to market conditions [1]. - The offering is made under a shelf registration statement effective since November 22, 2024, and will be conducted via a prospectus [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance Gyre's Phase 2 clinical trial of F351 for MASH-associated liver fibrosis, along with funding for research, development, manufacturing, and general corporate purposes [2]. Group 3: Management of the Offering - Jefferies is the lead book-running manager for the offering, with H.C. Wainwright & Co. serving as co-manager [3]. Group 4: Company Overview - Gyre Therapeutics is focused on developing and commercializing treatments for liver fibrosis, including MASH, and has a pipeline that includes various therapeutic programs in the U.S. and China [6].

Core Viewpoint - Elbit Systems Ltd. has announced a public offering of 1,365,450 ordinary shares priced at $375 per share, with gross proceeds expected to be approximately $512 million before deductions [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 204,817 shares at the public offering price [1]. - The offering is expected to close on May 23, 2025, subject to customary closing conditions [1]. - The shares will be listed for trading on the Nasdaq Global Select Market [1]. Group 2: Financial Information - The gross proceeds from the offering are anticipated to be around $512 million, assuming no exercise of the underwriters' option [2]. - Elbit Systems plans to use the net proceeds for general corporate purposes [2]. Group 3: Underwriters - BofA Securities, J.P. Morgan, Jefferies, and Morgan Stanley are acting as joint book-running managers for the offering [3]. - Barak Capital Underwriting is serving as a placement agent for the underwriters in Israel [3]. Group 4: Company Overview - Elbit Systems is a leading global defense technology company, employing approximately 20,000 people across five continents [6][7]. - The company reported revenues of $1.9 billion for the three months ended March 31, 2025, with an order backlog of $23.1 billion as of that date [7].

Core Viewpoint - Elbit Systems Ltd. announced a public offering of 1,365,450 ordinary shares, all of which will be sold by the company, with a potential additional 15% option for underwriters [1][2][3] Group 1: Offering Details - The offering is made under an effective shelf registration statement on Form F-3 filed with the SEC on May 21, 2025, which became effective immediately [3] - The net proceeds from the offering will be used for general corporate purposes [1] - The ordinary shares are expected to be listed for trading on the Nasdaq Global Select Market [1] Group 2: Underwriters - BofA Securities, J.P. Morgan, Jefferies, and Morgan Stanley are engaged as joint book-running managers for the offering [2] Group 3: Company Overview - Elbit Systems is a leading global defense technology company, employing approximately 20,000 people across five continents [5][6] - The company reported revenues of $1.9 billion for the three months ended March 31, 2025, and has an order backlog of $23.1 billion as of that date [6]

Core Viewpoint - Southwest Gas Holdings, Inc. is conducting a secondary public offering of 9,000,000 shares of Centuri Holdings, Inc. at a price of $17.50 per share, with an additional option for underwriters to purchase 1,350,000 shares [1][2] Group 1: Offering Details - The offering is expected to close on May 22, 2025, subject to customary closing conditions [1] - Icahn Partners and Icahn Partners Master Fund LP will purchase $50 million in shares of Centuri's common stock in a concurrent private placement at the same price per share as the public offering [2] - The shares are being offered under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission [4] Group 2: Underwriters and Management - J.P. Morgan, UBS Investment Bank, and Wells Fargo Securities are acting as joint lead book-running managers for the offering [3] - BofA Securities and Moelis & Company are serving as book-running managers, with additional co-managers including Baird, KeyBanc Capital Markets, and others [3] Group 3: Company Background - Southwest Gas Holdings, Inc. operates through its subsidiary Southwest Gas Corporation, providing natural gas services to over 2 million customers in Arizona, Nevada, and California [6] - Centuri Holdings, Inc. partners with regulated utilities to build and maintain energy networks across the U.S. and Canada [7]